The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2018-04, Vol.118 (8), p.1115-1122
Main Authors: El Ansari, Rokaya, Craze, Madeleine L., Diez-Rodriguez, Maria, Nolan, Christopher C., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Format: Article
Language:English
Subjects:
631/67/1347
692/53
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - diagnosis
Breast Neoplasms - genetics
Breast Neoplasms - pathology
c-Myc protein
Cancer Research
Cell Proliferation
Clinical outcomes
Cohort Studies
Drug Resistance
Epidemiology
ErbB-2 protein
Female
Fusion Regulatory Protein 1, Heavy Chain - genetics
Fusion Regulatory Protein 1, Heavy Chain - metabolism
Gene expression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genomics - methods
Humans
Immunohistochemistry
Medical prognosis
Molecular Medicine
mRNA
Multivariate analysis
Myc protein
Neoplasm Invasiveness
Oncology
Prognosis
Protein expression
Proteins
Proteomics
Risk factors
Tissue Array Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed at the genomic level, using METABRIC data ( n  = 1980), and at the proteomic level, using immunohistochemistry on tissue microarray (TMA) sections constructed from a large well-characterised primary BC cohort ( n  = 2500). SLC3A2 expression was correlated with clinicopathological parameters, molecular subtypes and patient outcome. SLC3A2 mRNA and protein expression were strongly correlated with higher tumour grade and poor Nottingham prognostic index (NPI). High expression of SLC3A2 was observed in triple-negative (TN), HER2+ and ER+ high-proliferation subtypes. SLC3A2 mRNA and protein expression were significantly associated with the expression of c-MYC in all BC subtypes ( p  
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-018-0038-5